Free Trial

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) CEO Sells $61,915.66 in Stock

PMV Pharmaceuticals logo with Medical background

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) CEO David Henry Mack sold 58,411 shares of the business's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $1.06, for a total value of $61,915.66. Following the transaction, the chief executive officer owned 536,133 shares in the company, valued at approximately $568,300.98. This represents a 9.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

PMV Pharmaceuticals Price Performance

NASDAQ PMVP traded up $0.11 during mid-day trading on Friday, reaching $1.21. The stock had a trading volume of 582,828 shares, compared to its average volume of 197,220. PMV Pharmaceuticals, Inc. has a 1 year low of $0.81 and a 1 year high of $1.82. The stock has a market cap of $62.86 million, a PE ratio of -1.03 and a beta of 1.49. The company has a fifty day moving average price of $0.99 and a 200 day moving average price of $1.18.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.03. As a group, equities research analysts expect that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current year.

Institutional Investors Weigh In On PMV Pharmaceuticals

Large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its stake in shares of PMV Pharmaceuticals by 2,282.8% during the 4th quarter. JPMorgan Chase & Co. now owns 24,591 shares of the company's stock valued at $37,000 after acquiring an additional 23,559 shares during the period. Velan Capital Investment Management LP bought a new position in PMV Pharmaceuticals in the 4th quarter worth approximately $53,000. Squarepoint Ops LLC boosted its stake in PMV Pharmaceuticals by 68.7% in the 4th quarter. Squarepoint Ops LLC now owns 73,015 shares of the company's stock worth $110,000 after purchasing an additional 29,722 shares during the period. Northern Trust Corp boosted its stake in PMV Pharmaceuticals by 23.2% in the 4th quarter. Northern Trust Corp now owns 107,340 shares of the company's stock worth $162,000 after purchasing an additional 20,190 shares during the period. Finally, Bridgeway Capital Management LLC boosted its stake in PMV Pharmaceuticals by 44.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 202,100 shares of the company's stock worth $305,000 after purchasing an additional 62,200 shares during the period. 90.20% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and set a $5.00 price target on shares of PMV Pharmaceuticals in a research report on Thursday, March 20th.

Check Out Our Latest Stock Analysis on PMV Pharmaceuticals

About PMV Pharmaceuticals

(Get Free Report)

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.

See Also

Should You Invest $1,000 in PMV Pharmaceuticals Right Now?

Before you consider PMV Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PMV Pharmaceuticals wasn't on the list.

While PMV Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines